VVOS VVOS
Company Profile ↓Company Overview
VVOS (VVOS) is a publicly traded company listed on with a market capitalization of $3.16M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $17.44M (+16.0% YoY); net profit $-21.23M.
- Trailing 12 Months Year-on-year growth — revenue +16.1%.
- 5-Year Trend Long-term compounding — revenue CAGR 8.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 8.89% |
| 1 Year: | 16.05% |
Stock Price Performance
| 1 Year: | -93.42% |
| 6 Months: | -77.59% |
| 3 Months: | -52.03% |
| 1 Month: | -28.89% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.43 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 93.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.20M | 3.27M | 3.29M | 3.45M | 4.50M | 4.55M | 3.64M | 4.18M | 4.25M | 3.86M | 3.40M | 3.30M | 3.42M | 4.05M | 3.86M | 3.02M | 3.82M | 6.78M | 3.82M | 5.14M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51M | 1.71M | 2.85M | 836.00K | 2.08M |
| Gross Profit | 2.42M | 2.73M | 2.58M | 2.69M | 3.62M | 3.18M | 2.55M | 2.59M | 2.50M | 2.34M | 2.10M | 1.75M | 1.94M | 2.65M | 2.33M | 1.51M | 2.11M | 3.94M | 2.99M | 3.06M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.43M | 6.97M | 8.67M | 9.37M | 9.67M |
| Operating Income | -2.56M | -1.42M | -1.82M | -3.41M | -4.06M | -5.50M | -6.64M | -6.96M | -5.41M | -5.00M | -4.52M | -3.64M | -3.79M | -1.94M | -2.65M | -3.92M | -4.87M | -4.73M | -6.38M | -6.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.74M | -4.56M | -4.35M | -5.94M | -6.16M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.86M | -5.01M | -5.40M | -6.95M | -7.75M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -2.58M | -1.41M | -1.81M | -3.40M | -4.04M | -5.45M | -5.33M | -6.99M | -5.43M | -1.70M | -5.53M | -2.09M | -3.76M | -1.93M | -2.62M | -3.86M | -5.01M | -5.40M | -6.95M | -7.68M |
| Diluted EPS | - | - | - | - | - | - | -0.25 | -0.33 | -6.40 | -1.72 | -4.62 | -1.75 | -1.63 | -0.60 | -0.40 | -0.45 | -0.55 | -0.49 | - | -0.52 |
| R&D Expense | - | - | - | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | 100.00K | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 11.39M | 13.07M | - | 16.02M | 13.80M | 15.03M | 17.44M |
| Cost of Revenue | - | - | - | 6.00M | 5.53M | 6.01M | 6.90M |
| Gross Profit | 8.66M | 10.41M | - | 10.02M | 8.27M | 9.02M | 10.54M |
| Operating Expenses | - | - | - | 35.05M | 25.57M | 20.19M | 30.44M |
| Operating Income | -10.58M | -12.04M | - | -25.03M | -17.30M | -11.17M | -19.89M |
| EBITDA | - | - | - | -24.36M | -16.68M | -10.59M | -18.59M |
| Interest Expense | - | - | 14.00K | 0 | - | - | - |
| Pretax Income | - | - | - | -23.84M | -13.58M | -11.14M | -21.23M |
| Tax Provision | - | - | 0 | 0 | - | - | - |
| Net Income | -10.75M | -12.06M | - | -23.84M | -13.58M | -11.14M | -21.23M |
| Diluted EPS | - | - | - | -25.90 | -11.14 | -2.22 | -2.07 |
| R&D Expense | - | - | 200.00K | 200.00K | 100.00K | 100.00K | 100.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.55M | 25.33M | - | 13.72M | 10.73M | 15.28M | 25.15M |
| Current Assets | - | - | - | - | 5.42M | 2.46M | 7.47M | 4.38M |
| Cash & Equivalents | - | 469.35K | 18.21M | - | 3.52M | 1.64M | 6.26M | 2.03M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 457.00K | 202.00K | 430.00K | 1.58M |
| Total Liabilities | - | 9.18M | 8.41M | - | 8.92M | 10.32M | 7.33M | 26.70M |
| Current Liabilities | - | 9.09M | 7.84M | - | 6.81M | 7.29M | 4.98M | 18.08M |
| Long Term Debt | - | 3.71M | 423.00K | - | - | - | - | 469.00K |
| Total Debt | - | - | - | - | 2.41M | 2.00M | 1.51M | 13.50M |
| Total Equity | 4.83M | -2.94M | 16.92M | - | 4.80M | 411.00K | 7.95M | -1.49M |
| Shares Outstanding | - | - | - | - | 920.48K | 1.83M | 5.89M | 9.29M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.34M | -5.68M | - | -19.59M | -11.95M | -12.69M | -15.26M |
| Investing Cash Flow | 86.22K | -120.00K | - | -924.00K | -853.00K | -568.00K | -7.53M |
| Financing Cash Flow | 4.47M | 23.54M | - | 0 | 10.92M | 17.88M | 18.56M |
| Capital Expenditure | -175.60K | -120.00K | - | -924.00K | -803.00K | -568.00K | -2.34M |
| Free Cash Flow | -5.52M | -5.80M | - | -20.51M | -12.75M | -13.26M | -17.60M |
| Net Change in Cash | - | - | - | -20.51M | -1.88M | 4.62M | -4.23M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 76.0% | 79.7% | - | 62.5% | 59.9% | 60.0% | 60.4% |
| Operating Margin % | -92.8% | -92.1% | - | -156.2% | -125.3% | -74.3% | -114.1% |
| Net Margin % | -94.4% | -92.3% | - | -148.8% | -98.4% | -74.1% | -121.7% |
| ROE % | 365.4% | -71.3% | - | -496.7% | -3,304.9% | -140.0% | 1,424.8% |
| ROCE % | 685.9% | -68.9% | - | -362.4% | -502.6% | -108.4% | -281.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VVOS
Vivos sleep apnea devices gain broader protection after new patent - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPcmdsTHB6ak5USEJicjlxdXBFR1FBNlI0VndEbFVvcy1WSlBqMUxYN0FnbGJXZzA2Y1Z6WGlEaEJwQXhoNVFWZ3BPZHBSMDczSU0zZ18ta0V3QkxlNFpnb2xkVTlucTRBUkJJMFlpRjFkLUxKSUloanlrN1NXVEpaZVJqbTdfanZVbWhPaH…
Vivos Therapeutics (VVOS) Stock Fair Value Falls After Analyst Target Cuts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNMmZ0ZXlhUURab0xKcVZ5S080SXVXNER6YUNSYWJLazJ0LWZDcnNfYTk0UU1CQUtza0VmUy1pM1h2WkNvdkFyMVFuTDlSb0ZOMUhaYUVsZGhmVnRPVE1pX0I3X2gtNUE5U3dYOXdBdFQxT1VlWVdlU2dQeVpBN19zYUNXUWRmeGR0M05SZm…
Price to sales forward of Vivos Therapeutics, Inc. – NASDAQ:VVOS - TradingView
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOemM3RmpQc19iWk9XMHJzZ0I4VW8yenMxVlhfcmo3RkQ1d3VVeUlNYU14aUhuRjA2d3pzLThhSC1XUFpxMDZ0V20xdTlMbGVkTHh2YzcyajdrVmZ3UmxtakZUaTZTSGRGTTRGcTRXT1Q3VXh1RXNybEhpUkpWU0hDbFVOMmRnNjFpWGJNVG…
Trending Stocks Today | Vivos Therapeutics Soars 36.3% Post-Market - Moomoo
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPSElaZWNFdzI2Y3ZETFRic3BPZjVUaWdaeVhBT19oQU1nQWl0MkQ0LXE0MS12T3hLTHJicG5uMHFMLTdtMndZZWlWUEFabVQ4Z0VabzJfb1kxa0pEWjFtTm5xUE1hMm1HckpyeGVoeTBOaHJmYTU5X0ljVlBtRV83emNUNEl2SlY5NjlRS0…
$VVOS stock is up 28% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQX05xYl96bC1HYnp1X19hc2I1aWY1b1BTTlJaSDdFNUFsQWpZeTkxQjNyUEU1OXMzal9ZdzZUY3RjeFhWOUxXVnYtWnBEalpFbzJGcFFCeXRqRkpXSHE2cXJ4ZUVaWk9lbVZSaEIzX3NsWTZFVWllakxERkZkbDY0R3d0X0pUOE9CS0NKVU…
VVOS - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE91VTBEOG8xWjR5NzZxSnpCNjZkUHVqTFktckRNbmhDSjNNMVBOX0daNjNyVlZxME5hTUM1NzJqR1BHMk1aZ0E?oc=5" target="_blank">VVOS</a> <font color="#6f6f6f">Finviz</font>…
VVOS — Frequently Asked Questions
What is the current share price of VVOS?
As of 2026-08-05 17:25 PDT, VVOS trades at $0.34 on NASDAQ/NYSE. Its 52-week range is $0.34 to $5.18.
What is the market capitalisation of VVOS?
VVOS has a market capitalisation of $3.16M on NASDAQ/NYSE.
What is the P/E ratio of VVOS?
VVOS trades at a trailing price-to-earnings (P/E) ratio of -0.16. Its price-to-book (P/B) ratio is -2.12.
Is VVOS a good stock to buy?
This page provides a data-driven analysis of VVOS, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.